Phenotypeca has the ‘go-to’ platform for the development of baker’s yeast strains for industrial-scale manufacture of vaccines, therapeutics and other recombinant proteins. These markets had over $200 billion in revenue globally in 2020.

    We offer an animal-free, sustainable option for these markets as well as other industrial applications.

    Our team were involved in developing extensive yeast breeding techniques and genome sequencing in the 1990s. They were also involved in creating and filing the patents for the first-generation baker’s yeast platform. They have developed processes for vaccines, therapeutics, and recombinant proteins such as Recombumin®, which have achieved EU and FDA approval.

    The Mission

    “To make medical treatments more affordable for everyone using baker’s yeast”

    Our Company

    We have the world’s largest unique collection of baker’s yeast strains bred and engineered for stable industrial recombinant protein production. With so many genetically distinct yeast strains as starting points for your protein of interest, we have a high chance of successfully developing a strain for your product.

    We have already worked on successful projects with vaccines, antibody fragments, and other recombinant therapeutic proteins. The team has extensive expertise in industrial protein manufacture, and in particular in a cGMP environment, from baker’s yeast strains.

    Our People

      • Dr Chris Finnis

        Intellectual Property and Projects Director

      • Professor Ed Louis

        Research and Development Director

      • Keith Williams

        Director

      • Dr Chris Finnis

        Intellectual Property and Projects Director

        PhD in Microbial Genetics from the University of Nottingham, MSc in Biochemical Engineering (UCL), Biotechnology BSc (Hons) from University of Leeds. 30-years industrial experience in yeast strain development for recombinant protein production. Royal Society Entrepreneur-in-Residence and inventor on multiple patents with a passion for bringing new products to the market. When not enjoying yeast-derived products, loves kayaking and the great outdoors.

      • Professor Ed Louis

        Research and Development Director

        PhD in Genetics from The University of California at Berkley, BSc in Biology and Mathematics from Clarkson University. Experienced in yeast genetics, genomics, and evolution; was a key part of the yeast genome sequencing project, now developing tools for exploiting its natural genetic/phenotypic variation. Thoroughly enjoys the products of yeast (wine, beer and bread).

      • Keith Williams

        Director

        MSc Biochemical Engineering, BSc Biological Sciences, Birmingham University. Experienced entrepreneur, innovator and business manager with extensive Life Science and Technology experience in the UK, European and US regulatory frameworks. Certified cricket nut.

      • Patrick Florent

        Chairman (Non-Executive)

      • David Grinham

        Non-Executive Director

      • Simon Chalk

        Non-Executive Director

      • Patrick Florent

        Chairman (Non-Executive)

        Patrick is a seasoned Executive with a broad and diverse experience in Industrial Operation, Enterprise Integration and Global Alliances at GSK Vaccines. Most recently, as Head of Global Strategic Partnership, Patrick was in charge of several strategic alliances in Japan, China, Singapore and Brazil and is a Board member of three joint ventures; the Japan Vaccines Company, Qualivax and Tian Yuan. Previously he was the PMO leader for Novartis Vaccines GSK Integration (2014 - 2017) and a Board member and advisor for CEPI.

      • David Grinham

        Non-Executive Director

        David is a Chartered Director and Fellow of the Institute of Directors and the RSA. He has held several executive and non-executive positions for international organisations, primarily in the Learning and Development, Higher Education and Assessment sectors. He is currently Chair of the Learning and Performance Institute International.

      • Simon Chalk

        Non-Executive Director

        Simon joins Phenotypeca with over 20 years industry experience, having worked with some of the biggest biopharmaceutical manufacturing organisations in the world. After obtaining an engineering degree, Simon went on to become a management consultant with specific focus on the biopharmaceutical manufacturing supply chain area.

        In 2002, Simon founded Biopharmaceutical Consulting and advised on a number of significant facility start up projects. In 2009 he was a founder of BioPhorum, a leading industry collaboration group, which has now become the most trusted environment for senior leaders from the biopharmaceutical industry to openly share and discuss emerging trends and challenges facing the industry. Simon also has strong skills as a facilitator and consultant, turning BioPhorum into a highly successful business, culminating in a private equity deal in 2018.

      • Marion Parrish

        HR Consultant

      • Matt Green

        Acting Finance Director

      • Dr Anton Hutter

        European & UK patent attorney

      • Marion Parrish

        HR Consultant

        Marion holds over 29 years of experience in HR and training across private and public sectors and is the founder of renowned HR Consultancy Marion Parrish. As a specialist in supporting visionary companies through rapid growth and expansion, she will be focused on implementing management and HR practices that ensure commercial excellence and continue to make Phenotypeca a great place to work.

      • Matt Green

        Acting Finance Director

        As interim Financial Director, Matt will focus on helping Phenotypeca to streamline its financial data, reporting and processes, increase transparency and implement the latest technologies to support the business on this exciting journey. As a lover of the great outdoors, outside of work, Matt can be found spending time with his family and running around big open spaces.

      • Dr Anton Hutter

        European & UK patent attorney

        Anton is a European & UK patent attorney and partner in our Venner Shipley’s Chemical & Life Science team. He specialises in biotechnology and pharmaceuticals. In particular, he has a deep understanding of molecular biology, biochemistry & genetics, genomics & proteomics, immunology-related inventions, including therapeutic antibodies & immuno-oncology, bioinformatics, biomarkers & diagnostics, peptides & protein chemistry, vaccines, pharmaceuticals and SPCs.

    Key Achievements

    June 2022

    Phenotypeca wins 2nd and 3rd commercial customers and continues to expand commercial offering

    October 2021

    Phenotypeca wins £1.0m Gates project and further IUK project to complete the PhenoDev™ and develop PhenoFull™ platform products, as well as start to grow the IP streams

    June 2021

    Phenotypeca moves to BioCity Nottingham, and wins first commercial customer and raises further £400,000 EIS seed funding

    October 2020

    Phenotypeca raises £300,000 SEIS and seed funding

    June 2020

    Phenotypeca wins 2x IUK and VaxHub projects to develop the PhenoStart™ and PhenoDev™ platform products

    October 2019

    Phenotypeca starts trading and Ed Louis joins as CSO and Patrick Florent as Chairman of the Board

    Get In Touch

    If you have any questions, or would like to find out more about our unique processes, please get in touch.

    Office Address

    Phenotypeca Ltd, BioCity Nottingham, Pennyfoot Street, Nottingham, NG1 1GF.

    Email: info@phenotypeca.com

    © Copyright 2022 Phenotypeca Ltd. All Rights Reserved.
    Phenotypeca Ltd is a limited company incorporated in England with registered number 11700555.

    Terms and Conditions | Privacy Policy

    Website built by IvyJack Communications Ltd